Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma

Biomedical Chromatography

Volumn 22, Issue 3, 2008, Pages 316-326

  Trivedi, Ravi Kumar ^a,b   Dubey, Pramod Kumar ^a   Mullangi, Ramesh ^b   Srinivas, Nuggehally R ^b  

^a JNTUH COLLEGE OF ENGINEERING   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Dog plasma; Hamster plasma; LC MS MS; Method validation; Pharmacokinetics; Torcetrapib

Indexed keywords

ACETONITRILE; ELECTROSPRAY IONIZATION;

DOG PLASMA; HAMSTER PLASMA; INTERNAL STANDARDS; IONIZATION TECHNIQUES; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; MULTIPLE-REACTION MONITORING MODES; RUNTIMES; TORCETRAPIB;

PHARMACOKINETICS;

ACETONITRILE; AMMONIUM ACETATE; TORCETRAPIB;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOG; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; HAMSTER; ION MONITORING; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROCESS DEVELOPMENT; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

CANIS FAMILIARIS; CRICETINAE;

EID: 41549097828     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.935     Document Type: Article

References (20)

1. Barter PJ and Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Current Opinion in Lipidology 2001; 12: 377-382.
2. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ and Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology 2003; 23: 160-167.
3. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, Patel M, Saxena A, Baliga A, Parekh H and Yadav G. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. Journal of Chromatography B 2007; 852: 115-121.
4. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME and Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arteriosclerosis Thrombosis and Vascular Biology 2004; 24: 490-497.
5. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Jounal of American Society for Mass Spectrometry 2003; 14: 1290-1294.
6. Doggrell SA. Inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. Expert Opinion on Investigational Drugs 2006; 15: 99-106.
7. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001; 103: 2213-2218.
8. Hamashima Y. Acid-base catalysis of chiral Pd complexes: development of novel catalytic asymmetric reactions and their application of synthesis of drug candidates. Chemical and Pharmaceutical Bulletin 2006; 54: 1351-1364.
9. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, Bervoas-Martin S, Chevalier P, Grandjean D, Lagorce P, Lallier M, Laparra MC, Laurentie M and Nivet JC. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conference to the laboratory. Analytica Chimica Acta 1999; 391: 135-148.
10. Jensen GB and Hampton J. Early termination of drug trials. British Medical Journal 2007; 334: 326.
11. Lee SD, Wasan KM, Calcagni A, Avery M, McCush F and Chen C. The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influence by differences in plasma lipid concentrations. Pharmaceutical Research 2006; 23: 1025-1030.
12. Link B, Haschke M, Wenk M and Krahenbuhl S. Determination of midazolam and its hydroxymetabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2007; 21: 1531-1540.
13. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne MW and Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipo-proteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arteriosclerosis Thrombosis 1991; 11: 797-804.
14. Nitin M, Rajanikanth M, Lal J, Madhusudanan KP and Gupta RC. Liquid chromatography-tandem mass spectrometric assay with a novel method of quantitation for the simultaneous determination of bulaquine and its metabolite, primaquine, in monkey plasma. Journal of Chromatography B 2003; 793: 253-263.
15. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16.
16. Sacks FM. Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations American Journal of Cardiology 2002; 90: 139-143.
17. Tall AR, Jiang XC, Luo Y and Silver D. 1999 George Lyman Duff Memorial Lecture: Lipid Transfer Proteins, HDL Metabolism and Atherogenesis. Arteriosclerosis Thrombosis and Vascular Biology 2002; 20: 1185-1188.
18. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV), 2001. Available at: http://www/fda.gov/ cder/guidance/index.htm
19. von Eckardstein A, Nofer JR and Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arteriosclerosis Thrombosis and Vascular Biology 2001; 21: 13-27.
20. Watts GF. The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clinical Science 2002; 103: 595-597.